UniQure said the U.S. Food and Drug Administration no longer agreed that clinical data for the Dutch company's gene therapy ...

The latest announcement is out from Cellectis SA ( (CLLS) ).

The CEO highlighted results from the REMAIN-1 Midpoint Cohort, where "Revita-treated patients lost an additional 2.5% of total body weight, while patients in the sham group regained about 10%, a ...

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) just unveiled an update. On November 13, 2025, Eupraxia Pharmaceuticals announced additional 52-week ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

Digital health is transforming healthcare delivery by integrating advanced information technologies to improve outcomes, ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. For as long as I’ve worked in data and analytics, predictions of disappearing roles have ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung ...